A Study of the Transition From Cangrelor to Ticagrelor, and Ticagrelor to Cangrelor in Patients With Coronary Artery Disease

Trial Profile

A Study of the Transition From Cangrelor to Ticagrelor, and Ticagrelor to Cangrelor in Patients With Coronary Artery Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2015

At a glance

  • Drugs Cangrelor (Primary) ; Ticagrelor (Primary)
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Therapeutic Use
  • Sponsors The Medicines Company
  • Most Recent Events

    • 16 May 2014 The number of treatment arms changed from 2 (Ticagrelor and Cangrelor) to 4 (Arm 1- Cangrelor IV + Ticagrelor 180mg at 0.5 hr and arm 2- at 1.5 hr , arm 3- Ticangrelor IV + Ticagrelor 90mg (7 doses) and arm 4- 90 mg in 6 doses.)
    • 09 Oct 2013 Study completion announced in a media release issued by The Medicines Company.
    • 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top